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To the Editor: Fluoroquino-
lones are broad-spectrum antimicro-
bial drugs used to treat many clinical 
infections. Salmonellosis is treated 
with ﬂ  uoroquinolones only in elderly 
or immunocompromised patients, but 
these drugs are also used for treating 
patients with enteric fever, invasive 
disease, or long-term salmonellae 
carriage. High-level ﬂ  uoroquinolone 
resistance is uncommon, but reduced 
susceptibility is increasing.
Since 1998, plasmid-mediated 
quinolone resistance encoded by qnr 
genes A, B, and S that confer low-
level resistance to nalidixic acid and 
reduced susceptibility to ciproﬂ  oxacin 
has been identiﬁ  ed in several entero-
bacterial species, including Salmo-
nella. Their clinical importance is in 
facilitating resistance to potentially le-
thal levels of quinolone. Additionally, 
qnr genes are often associated with 
strains that produce extended-spec-
trum β-lactamases.
We recently reported identiﬁ  ca-
tion of qnr genes in Salmonella in the 
United Kingdom (1). Most isolates 
were associated with the Far East. 
Two isolates of S. Virchow were part 
of an outbreak associated with im-
ported cooked chicken from Thailand. 
During October 2006–April 2007, we 
monitored qnr genes in nontyphoidal 
salmonellae isolated in the United 
Kingdom that expressed reduced 
susceptibility to ciproﬂ  oxacin  (MIC 
0.125–1.0  μg/mL) with concomitant 
susceptibility to nalidixic acid (MIC 
<16  μg/mL). This resistance pheno-
type is a useful marker for the qnr 
gene as the sole quinolone resistance 
determinant (1). 
Recent studies showed that iso-
lates of Salmonella  spp. and Esch-
erichia coli with decreased suscep-
tibility to ciproﬂ  oxacin (MICs >0.06 
μg/mL and 0.5 μg/mL, respectively), 
but with susceptibility or intermedi-
ate resistance to nalidixic acid (MIC 
8–16 μg/mL and 4–8 μg/mL, respec-
tively), all had qnrA or qnrS genes 
but lacked mutations in the topoi-
somerase genes (2,3). Strains with 
ciproﬂ  oxacin MICs >1 μg/mL were 
also included to monitor involve-
ment of qnr genes in development of 
high-level ciproﬂ  oxacin  resistance. 
Breakpoint concentrations used are 
based on long-term studies within the 
Health Protection Agency Laboratory 
of Enteric Pathogens. Ciproﬂ  oxacin 
Etest (AB Biodisk, Solna, Sweden) 
results were interpreted according to 
manufacturer’s procedures. A total 
of 45 Salmonella spp. strains were 
tested. Screening for qnr genes by 
multiplex PCR identiﬁ  ed 37 isolates 
with qnrS and 2 carrying qnrB vari-
ants (Table) (4). However, the qnrB 
primer pair in this multiplex did not 
fully match all qnrB gene variants. 
PCR and sequencing using primers 
FQ1 and FQ2 (5) and qnrS-F and 
qnrS-R (1), were used to identify spe-
ciﬁ  c qnrB and qnrS gene variants.
The qnrS1-positive salmonellae 
belong to serotypes Typhimurium 
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(21 isolates), Virchow (10), and 
Corvallis (6). Most S. Typhimurium 
isolates were either deﬁ  nitive phage 
type 120 or 193, and most S. Vir-
chow isolates were phage type 43 
(Table). Thirteen qnrS1-positive 
isolates were from patients who re-
ported recent travel to Egypt, India, 
Malaysia, Morocco, Thailand, or an 
undisclosed destination.
Twelve isolates from patients who 
had not traveled abroad were assumed 
to be from UK-acquired infections. S. 
Virchow isolates had been associated 
with cooked chicken from Thailand 
(1), and qnrS1 has recently been de-
scribed in S. Corvallis strains from hu-
mans in Denmark or isolated in Thai-
land from humans, chicken, pork, and 
beef (3). Comparison of pulsed-ﬁ  eld 
gel electrophoresis patterns and resis-
tance phenotypes of qnrS1-positive S. 
Corvallis strains identiﬁ  ed  common 
types, suggesting that some UK pa-
tients may have acquired S. Corvallis 
from chicken from Thailand.
Thirteen isolates showed resis-
tance to ceftriaxone, cefotaxime, or 
ampicillin. Plasmids with qnr genes 
have been found to co-transfer TEM, 
SHV, and CTX-M genes (1,5,6). Co-
transmission of ﬂ  uoroquinolone and 
β-lactamase resistance is clinically 
important because co-selection of 
resistance by use of either drug may 
occur.
Twenty-one qnrS1-positive S. Ty-
phimurium were subtyped by variable 
number tandem repeat (VNTR) analy-
sis to determine whether the increase 
was caused by spread of >1 distinct 
strains (7). Twenty isolates produced 
1 of 3 related proﬁ  les (loci of VNTR 
proﬁ   les are ordered STTR9-STTR5-
STTR6-STTR10pl-STTR3): 1–4-0–0-
3, 9 isolates; 1–5-0–0-3, 3 isolates; or 
1–6-0–0-3, 8 isolates. Alleles 4 and 5, 
and 5 and 6 at locus STTR5 only dif-
fered by an extra 6-bp repeat, which 
suggests a clonal relationship between 
the qnrS1-positive S. Typhimurium in 
this study (Table) (8). S. Typhimurium 
isolates with the 1–6-0–0-3 proﬁ  le 
have been isolated from tourists re-
turning from Asia (7), which suggests 
that the UK qnrS1-positive  S. Ty-
phimurium isolates have originated in 
the Far East.
These  ﬁ   ndings show increased 
occurrence of qnr genes, particularly 
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Table. Isolates of Salmonella enterica with plasmid-mediated qnr genes, United Kingdom, October 2006–April 2007 
Salmonella 
serotype  Phage type* No. isolates  VNTR profile†
Ciprofloxacin
MIC (μg/mL)‡
Additional resistance to 
antimicrobial drugs§ qnr identified
Corvallis – 1 – 0.25 S, Su, T  qnrS1
Corvallis – 2 – 0.38 S,  Su,  T qnrS1
Corvallis – 1 – 1.0 S, Su, T ,Cf  qnrS1
Corvallis – 1 – 0.25 None qnrS1
Corvallis – 1 – 0.38 None qnrS1
Schwarzengrund – 1 – 0.25 T qnrB5
Typhimurium DT120 4 1–6-0–0-3  0.38 S, Su, T  qnrS1
Typhimurium DT120 3 1–6-0–0-3  0.50 S, Su, T  qnrS1
Typhimurium DT120 3 1–4-0–0-3  0.38 S, Su, T  qnrS1
Typhimurium DT120 1 1–4-0–0-3  0.50 S, Su, T  qnrS1
Typhimurium DT120 1 1–4-0–0-3 0.38 None qnrS1
Typhimurium DT120 1 1–5-0–0-3  0.38 S, Su, T  qnrS1
Typhimurium DT193 1 1–6-0–0-3  0.50 S, Su, T  qnrS1
Typhimurium DT193 1 1–4-0–0-3  0.38 C, S, Su, Sp, T, Tm  qnrS1
Typhimurium DT193 1 1–4-0–0-3  0.38 S, Su, T  qnrS1
Typhimurium DT193 2 1–5-0–0-3  0.38 S, Su, T  qnrS1
Typhimurium DT193 1 1–4-0–0-3 0.50 A,  Su  qnrS1
Typhimurium 49b 1 1–4-19–1-3  0.25 A, G, Ne, K, S, Su, Sp, T, Tm, 
Ak, Cx, Cr, Cf, Cn, Ct 
qnrB2
Typhimurium NC 1 1–4-0–0-3  0.25 S, Su, T  qnrS1
Typhimurium UT 1 3–8-19–1-2  >32 A, C, G, S, Su, Sp, T, Tm, Fu, 
Nx
qnrS1
Virchow 43 5 – 1.0 A, Fu, Nx  qnrS1
Virchow 43 2 – 1.5 A, Fu, Nx  qnrS1
Virchow 25a 1 – 0.75 Tm qnrS1
Virchow 11 1 – 1.0 A, Fu, Nx  qnrS1
Virchow NC 1 – 1.5 A, C, G, Ne, K, S, Su, Sp, T, 
Tm, Fu, Nx, Cx, Cr, Cf, Cn, Ct 
qnrS1
*DT, definitive type; NC, does not conform to a recognized pattern; UT, untypeable. 
†VNTR, variable number tandem repeat. Loci of the VNTR profiles are presented in the following order: STTR9-STTR5-STTR6-STTR10pl-STTR3. The 
number 0 in the VNTR profile represents cases with no amplification of PCR product. 
‡Determined by Etest.
§Antimicrobial drugs (breakpoint final concentrations): S, streptomycin (16 mg/L); Su, sulfonamide (64 mg/L); T, tetracycline (8 mg/L); Cf, cefuroxime (16 
mg/L); C, chloramphenicol (8 mg/L); Sp, spectinomycin (64 mg/L); Tm, trimethoprim (2 mg/L); A, ampicillin (8 mg/L]; G, gentamicin (4 mg/L); Ne, 
neomycin (8 mg/L) K, kanamycin (8 mg/L); Ak, amikacin (4 mg/L); Cx, cefalexin (16 mg/L); Cr, cefradine (16 mg/L); Cn, ceftriaxone (1 mg/L); Ct, 
cefotaxime (1 mg/L); Fu, furazolidone (8 mg/L); Nx, nalidixic acid (16 mg/L). LETTERS
qnrS1, in nontyphoidal salmonellae in 
the United Kingdom. These data are 
in contrast to those of recent studies 
in the United States and France, which 
show low incidences of qnrS genes in 
larger strain collections (9,10). The 
qnr phenotype is in contrast to resis-
tance mediated by mutations in the 
topoisomerase genes whereby 1 mu-
tation confers low-level resistance to 
ﬂ   uoroquinolones and full resistance 
to nalidixic acid. Our previous study 
demonstrated that qnrS1 was sufﬁ  -
cient to cause decreased susceptibility 
to ciproﬂ  oxacin in the absence of mu-
tations in gyrA (1). In this study, a qnr 
gene was sufﬁ  cient to increase the cip-
roﬂ  oxacin MIC to 0.38–0.75 μg/mL. 
In addition, a qnr gene contributed to 
high-level ciproﬂ  oxacin resistance in 
10 isolates, thereby potentially jeopar-
dizing ﬁ  rst-line treatment of vulnera-
ble patient groups with ciproﬂ  oxacin.
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Saksenaea 
vasiformis 
Infection, 
French Guiana 
To the Editor: The Zygomycetes 
are a class of ﬁ  lamentous fungi that are 
ubiquitous in the environment. Most 
of the species known to cause human 
or animal infections belong to a few 
genera within the order Mucorales. 
Saksenaea vasiformis, isolated from 
soil in India and described by Saksena 
in 1953, was reported to cause human 
infection for the ﬁ  rst time by Ajello et 
al. (1). We report a case of a cutane-
ous lesion caused by S. vasiformis in 
French Guiana.
A nonimmunocompromised 47-
year-old woman with a long history of 
non–type 1 diabetes mellitus, who had 
lived in French Guiana for many years, 
was admitted to Cayenne Hospital on 
November 18, 2005, with a cutaneous 
lesion of the abdominal wall and a fe-
ver that had lasted for 5 days before 
she was hospitalized. A skin biopsy 
specimen was obtained, and the ﬁ  rst 
surgical debridement was performed 
on day 4 of hospitalization. A diagno-
sis of zygomycosis was made after di-
rect examination and histopathologic 
examination of the tissue samples. 
Treatment was initiated on day 8, be-
ginning with liposomal amphotericin B 
and itraconazole for 10 days, followed 
by liposomal amphotericin B alone 
for 12 days. Persistence of necrotic 
tissues at the infection site required 
additional surgical debridement on 
day 10. Histopathologic examination 
of the resected tissues showed dam-
aged hyphae of zygomycetes. Reso-
lution of clinical signs was excellent. 
Additional biopsy specimens taken by 
the end of treatment on day 21 were 
negative for fungi by direct examina-
tion and culture. Finally, a cicatrix was 
formed.
Histologic examination of the 
initial excised tissues showed a local-
ized periumbilical cutaneous lesion of 
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